Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05435066 · ClinicalTrials.gov registry record

Development and Validation of Harbinger Health Test for Early Cancer Detection

A clinical trial of Cancer, sponsored by Harbinger Health.

Completed
Registry status
8,038
Enrollment target
20
Study locations

NCT05435066 is a study of Cancer that has completed, run by Harbinger Health. The registered enrollment target is 8,038 participants, above the 3,478-participant average among 615 other Cancer trials with a reported enrollment target (131% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05435066, a study of Cancer, has completed, sponsored by Harbinger Health.

COMPLETED
Registry status
8,038 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detection.

Conditions Studied

Cancer

Interventions

  • DIAGNOSTIC_TEST Harbinger Health Test

Study Locations (20)

Florida

  • Central Florida Pulmonary Group - Altamonte Springs - Altamonte Springs
  • ENT and Allergy Associates of Florida, LLC - Boca Raton
  • Plastic Surgery Specialists of Boca Raton - Boca Raton
  • ENT and Allergy Associates of Florida, LLC - Boca Raton
  • South Florida Center for Gynecologic Oncology - Boca Raton
  • Urology Center of South Florida - Boynton Beach
  • Advanced Cancer Surgery and Digestive Health - Boynton Beach
  • ENT and Allergy Associates of Florida, LLC - Brandon

California

  • Pacific Cancer Medical Center - Anaheim
  • Central California ENT Medical Group - Fresno
  • South Coast Gynecologic Oncology, Inc - San Diego
  • South Coast Gynecologic Oncology, INC - San Diego
  • Sansum Clinic - Santa Barbara
  • Gynecologic Oncology Associates - Torrance

Alaska

  • Alaska Oncology and Hematology, LLC - Anchorage
  • Alaska Womens Cancer Care - Anchorage

Alabama

  • Southern Cancer Center - Daphne

Arizona

  • Arizona Oncology Associates HAL - Prescott Valley

Colorado

  • Colorado Primary Health Care - Littleton

Delaware

  • Medical Oncology Hematology Consultants, PA - Newark

Trial Details

FieldValue
Enrollment Target 8,038 participants
Start Date 2022-06-21
Est. Completion 2025-06-11

Sponsor

Harbinger Health

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05435066

The ClinicalTrials.gov registry entry for NCT05435066 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8,038 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,478-participant average among 615 other Cancer trials with a reported enrollment target (131% higher). The listed sponsor is Harbinger Health, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Harbinger Health Test is the first listed.

NCT05435066 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alaska.

Frequently Asked Questions

What is clinical trial NCT05435066 about?

NCT05435066 is a clinical study titled "Development and Validation of Harbinger Health Test for Early Cancer Detection". This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and a...

What is the current status of trial NCT05435066?

This trial is currently completed. The enrollment target is 8,038 participants. The study started on 2022-06-21. Estimated completion is 2025-06-11.

What conditions does trial NCT05435066 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT05435066?

The interventions under investigation include: Harbinger Health Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05435066?

This trial is sponsored by Harbinger Health, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05435066 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.